Introduction
============

Cystic fibrosis, is the most common lethal autosomal recessive disorder in the Caucasian population, affecting one in 2,500 to 3,000 newborns and 70,000 people worldwide (C. G. App, Epidemiology). In 1938, CF was differentiated from celiac disease and named "cystic fibrosis of the pancreas" by [@B6]; [@B26]). Paul di Sant' Agnese, discovered the sweat electrolyte defect, and the standardization of the sweat test in 1959 made the diagnosis of CF accurate ([@B40]; [@B134]). Thirty years later, [@B96] discovered the gene responsible for CF, (*CFTR*), located on human chromosome 7. In 1989, they established the basic defect to be in a cAMP-regulated chloride channel ([@B131]). Since then, an explosion of basic and clinical research has led to therapeutic progress, and the median age of survival today ranges from 40 to 53 years old, with the highest in Canada, which is a remarkable improvement from only 6 months in 1938 ([@B96]; [@B101]).

In addition, CF is caused by the dysfunction or absence of the CFTR channel from the exocrine tissues due to mutations in the gene ([@B96]). While more than 2,000 mutations have been reported to date, the most common disease-causing mutation, occurring in 70% of patients, is F508del, a deletion of three nucleotides that results in the loss of phenylalanine (F) at the 508th position on the protein.

Respiratory failure is the major cause of death but as a multiorgan disease, CF also causes PI, intestinal obstruction and malabsorption, biliary cirrhosis and congenital bilateral absence of the vas deferens ([@B32]; [@B135]; [@B126]; [@B133]; [@B69]).

Animal models are essential tools for understanding and comprehensively investigating CF pathophysiology. Each model is unique and variably resembles human CF manifestations with variable ortholog CFTR protein identity (Table [1](#T1){ref-type="table"}). This review describes the availability of various animal models for CF and how useful they are for studying disease manifestation and progression in the lungs, intestines and other affected organs.

###### 

Amino acid identity in CFTR orthologs.

  Species     CFTR aa Identity vs. humans   Reference
  ----------- ----------------------------- -----------
  Mouse       78%                           [@B121]
  Pig         93%                           [@B90]
  Ferret      92%                           [@B38]
  Rat         75.5%                         [@B124]
  Zebrafish   55%                           [@B72]
  Sheep       91%                           [@B55]
                                            

Percentage of amino acid identity of CFTR orthologs from animal models described in this review, and compared to human CFTR.

Murine Models in Cystic Fibrosis Research
=========================================

The first genetically modified mouse models of CF disease were created 3 years after the identification of the *CFTR* gene by homologous recombination in embryonic stem cells through targeting a mutation to a specific site in the murine genome ([@B21]; [@B42]). Cloning of the mouse homolog of the human *CFTR* gene, which is located on mouse chromosome 6, revealed a 78% AA sequence homology to the human CFTR protein ([@B121]; [@B34]). To our knowledge, 14 more mouse models have been described in the literature to date with different characteristics, grouping them in two categoriess (Table [2](#T2){ref-type="table"}) ([@B87]; [@B95]; [@B30]; [@B22]; [@B56]; [@B127]; [@B137]; [@B29]; [@B102]; [@B38]). The first category consists of those models in which the *CFTR* gene was disrupted using a "replacement strategy" or an "insertional strategy." A replacement strategy causes an interruption of the *CFTR* gene and generates complete nulls ("knockout": KO) with no normal CFTR protein production, while with the "insertional strategy" a low amount (∼10%) of normal mouse CFTR mRNA is produced ([@B25]; [@B107]). The models generated by an "insertional strategy" method are also referred as "residual function" models ([@B25]). Phenotypic differences are observed between the absolute nulls and the residual function models due to the low amount of normal *CFTR* expression in the latter.

###### 

Murine models used in cystic fibrosis research.

  CF mice models                                                       Cftr mRNA                                      Survival to maturity   Reference
  -------------------------------------------------------------------- ---------------------------------------------- ---------------------- -----------
  **Knockout models** (replacement method)                                                                                                   
  *Cftr*^tm/Unc^                                                       No WT mRNA detectable                          \<5%                   [@B109]
  *Cftr*^tm/Cam^                                                                                                      \<5%                   [@B95]
  *Cftr*^tm/Hsc^                                                                                                      25%                    [@B102]
  *Cftr*^tm3Bay^                                                                                                      40%                    [@B56]
  *Cftr*^tm3Uth^                                                                                                      25%                    [@B132]
  **Residual function models** (insertional method)                                                                                          
  *Cftr*^tm/Hgu^                                                       10% of WT                                      90%                    [@B132]
  *Cftr*^tm/Bay^                                                       \<2% of WT                                     40%                    [@B87]
  **F508del models** (replacement-gene targeting method)                                                                                     
  *Cftr*^tm2Cam^                                                       30% of WT                                      \<5%                   [@B22]
  *Cftr*^tm/Kth^                                                       Decreased levels of mutant mRNA in intestine   40%                    [@B137]
  **F508del models** (Hit and Run method)                                                                                                    
  *Cftr*^tm/Eur^                                                       Normal level of mutant mRNA                    90%                    [@B102]
  **Models with other mutations**                                                                                                            
  *Cftr*^tm2Hgu^ (G551D- replacement-gene targeting method)            50% of WT                                      65%                    [@B132]
  *Cftr*^tm3Hgu^ (G480C- Hit and Run method)                           Normal level of mutant mRNA                    90%                    [@B132]
  *Cftr*^tm2Uth^ (R117H- replacement-gene targeting)                   5--20% of WT                                   95%                    [@B132]
  **Transgenes**                                                                                                                             
  Tg (FABPCFTR): correction of intestinal obstruction                  --                                             1.5--8.5 months        [@B138]
  Tg (CCSPSsnn 1b): βENaC over-expression (model of CF-lung disease)   --                                             40%                    [@B132]
  VIP-KO: CF-like phenotype in lung and intestine                      Normal level of WT                             Normal                 [@B4]
                                                                                                                                             

Levels of Cftr mRNA expression, compared to WT Cftr mRNA, are indicated when known. Survival rates at maturity refers to after weaning.

The second category contains mouse models that replicate known clinical mutations in CF, such as the Class II F508del (*Cftr*^tm1Eur^, *Cftr*^tm1Kth^, and *Cftr*^tm2Cam^) and Class III, G551D (*Cftr*^tm1G551D^) ([@B29]; [@B69]) utilizing a replacement-gene targeting strategy or a double homologous recombination method, also known as a "hit and run" procedure ([@B57]; [@B25]). In this category, survival rates, disease severity and pathology vary from model to model. The variations are attributed to different types of mutations, levels of mRNA expression, environmental factors and genetic backgrounds that can be responsible for various levels of activity of modifier genes in the mouse strains used ([@B120]; [@B107]). Moreover, because CF mutant mice are less fertile than normal mice, breeding CF mutant mice from heterozygous animals is strongly recommended to avoid phenotypic abnormalities and experimental variability ([@B137]). Lastly, gender and age are factors that should be considered especially for studying the progression of lung disease.

In a recent study, [@B77] generated a G542X CF mouse model with CRISPR/Cas9 gene editing method. 40.9% of founder mice expressed the G542X mutation and this new clone was generated in approximately 3 months, whereas traditional methods using embryonic stem cells, would necessitate 1--2 years to obtain the desired mouse colony. These mice have decreased CFTR expression and a lack of CFTR function in the airways and intestine; they have low survival rates due to intestinal obstruction. Pharmacological read-through of the G542X mutation in this mouse model enables functional CFTR protein production, making this model very interesting for further investigation of non-sense mutations ([@B122]; [@B78]).

Do Cystic Fibrosis Mice Develop Spontaneous Lung Disease?
---------------------------------------------------------

Progressive lung disease with respiratory failure is a major clinical concern that causes 95% of the morbidity and mortality in patients with CF. Lung disease develops over recurrent exacerbations of pulmonary infections caused by a large spectrum of bacterial species including *Staphylococcus aureus*, *Haemophilus influenza*, *Pseudomonas aeruginosa* and the *Bcc* ([@B120]; [@B37]). *P. aeruginosa* is persistent in human lungs with CF and chronic pulmonary infection is inevitable, despite antibiotic therapies, with biofilm-forming cells of a mucoid phenotype in more severe advanced infections. Spontaneous colonization with the above pathogens has not been detected in mice models unless a pathogen challenge was applied.

[@B68] designed a model from a single genetic background (congenic), C57BL/6J *Cftr*^tm1Unc^/*Cftr*^tm1Unc^, that under specific pathogen-free conditions, developed spontaneous and progressive lung disease ([@B50], [@B51]). Loss of mucociliary transport, post-bronchiolar hyperinflation of alveoli, and parenchymal interstitial thickening with indication of fibrosis and inflammatory cell recruitment characterize the lung disease in this congenic model ([@B68]). It also showed reduced control of the *P. aeruginosa* infection. Acinar and alveolar over inflation, reflect small airway obstructions that are observed in the early stages of CF in humans ([@B50]). Later on, more studies boosted our knowledge with significant observations in CF pulmonary pathology using mice that were not exposed to pathogens. Thus, excessive inflammation was noticed in *Cftr*^tmr1Hgu^ mice, MCC dysfunction in *Cftr*^tm1Hgu^ and *Cftr*^tm1Unc^ mice, goblet cell hyperplasia with ASL depletion in the nasal epithelium of *Cftr*^tm1Unc^ mice, and a distal extension of SMGs in *Cftr*^tm1Hgu^ and *Cftr*^tm1G551D^ mice ([@B23]; [@B136]; [@B120]; [@B107]). The *Cftr*^tm1G551D^ model demonstrated defective pulmonary clearance and a high sensitivity to *P. aeruginosa* ([@B79]).

To date, many research groups using congenic mice are still trying to develop methods for *P. aeruginosa* inoculation that would mimic chronic infection with this persistent pathogen. Techniques such as intratracheal inoculation of bacteria-loaded agar beads or seaweed alginate must be used to reproduce the human lung phenotype with *P. aeruginosa*.

The fact that CF mice do not develop airway's infections led [@B108] to investigate the reasons why mice have functioning airway's host defenses compared to humans and pigs with CF. This interesting study demonstrated that, in addition to the presence of Ca^+^-activated anion channels, mice also express small amounts (1--10%) of the non-gastric H^+^/K^+^ adenosine triphosphatase ATP12A transcripts, which catalyzes the hydrolysis of ATP coupled with the exchange of H^+^ and K^+^ ions across the plasma membrane. Consequently, mouse airways, including those in CF models, secrete low levels of H^+^ maintaining the pH of the ASL unaltered. The authors showed that the over-expression of ATP12A in CF mice airways caused acidification of the ASL, impairment of airway host defenses as well as increased amount of bacteria. These data suggest ATP12A as a potential therapeutic target for CF disease treatment ([@B108]).

[@B33] described a promising long-living congenic *Cftr^-/-^* model bred in the C57BL/6 background that displays the human lung pathology with signs of inflammation, presence of macrophages, tissue damage, and acinar dilation ([@B33]). Defective bacterial clearance, increased levels of pro-inflammatory factors, and inflammation was demonstrated using *Cftr*^tm1Unc^ and *Cftr*^tm1G551D^ mice ([@B58]; [@B79]; [@B128]). Macrophages are the most commonly found immune cells in the lung that play a significant role in bacteria eradication from the airways through phagocytosis. The input of macrophages polarization and plasticity in CF disease progression is still undefined. Studies in CF mice have shown that macrophages are unable to degrade internalized pathogens such as *P. aeruginosa* and *Bcc* ([@B11]; [@B70]). More specifically, *Cftr^-/-^* mice challenged with *P. aeruginosa* had increased IL-8, IL-6, and TNF-alpha levels and decreased IL-10 level, indicating that the absence of CFTR can cause excessive lung inflammation ([@B11]). Additionally, the number of both alveolar and peritoneal macrophages was high in F508del mice treated with LPS, illustrating their adaptability in the airway environment ([@B11]). CF mice may not be able to develop acute lung disease as patients with CF do, but they have been successfully used to demonstrate a defective autophagy mechanism which can lead to lung hyper-inflammation ([@B74]). An increasing amount of literature on CF macrophages is becoming available ([@B7]; [@B12], [@B13]; [@B80]; [@B1]; [@B110]; [@B70]).

[@B139] generated a transgenic "β-ENaC" mouse model to recapitulate the pathophysiology of the CF lung. This model, which over-expresses the β subunit of the ENaC with increased Na^+^ absorption, presented with ASL depletion, reduced MCC with airway mucus obstruction, goblet cell hyperplasia, chronic lung inflammation, and high mortality related to lung disease ([@B139]). Nonetheless, even this interesting model failed to replicate the spontaneous bacterial infection that develops in patients with CF ([@B139]).

Overall, while the above-mentioned methods and murine models further our understanding of CF lung abnormalities, they do not provide any information on how the disease starts and the development of early stages of infection and inflammation. Furthermore, the general notion that mice do not show "spontaneous" lung pathology could be misleading. Many factors play a role in this. The short life span of mice and clean or sterile environment under which the experiments are conducted are not comparable with the conditions for human lungs with CF that are continuously challenged with various pathogens along their lifetime. In addition, diverse genetic background is an important factor, while low levels of residual CFTR protein expression in some models affect the disease severity. Moreover, the size of the airways and the presence of a non-CFTR calcium-activated Cl^-^ channel (CACC) in parallel with CFTR and other dissimilarities in lung disease between humans and mice models ([@B21]; [@B42]; [@B69]) can account for differences in resistance to bacteria.

Submucosal Glands to Study Fluid Secretion Defects
--------------------------------------------------

Submucosal glands lining the cartilaginous airways are responsible for maintaining sterility in the airways by secreting antimicrobial defenses, such as lysozyme, lactoferrin, defensins, bicarbonate, and others ([@B104]; [@B64]). Moreover, they secrete mucus when stimulated with Ca^+^ -elevating agonists, for example acetylcholine (ACh) or carbachol (CCh), and/or cAMP agonists, such as forskolin (FSK) or VIP, and contain serous cells that express high levels of CFTR ([@B10]). In CF airway glands, the synergy between cAMP and calcium signaling is lost, and glands do not respond to VIP or FSK. In humans, SMGs extend into the bronchi, while, in mice they are confined to the trachea. Congenic mice models, especially those with a C57BL/6 genetic background, have been used to study SMG dysfunction since these mice show increased airway abnormalities and are prone to infection with *P. aeruginosa.* [@B45] mentioned that mice have very few SMGs ([@B45]). However, in a study of tracheal SMG secretion in *Cftr^-/-^* mice, Ianowski et al.(2007) observed that the upper trachea contains only 15--20 airway glands in wild-type (WT) mice and an abundance of glands in CF-KO mice ([@B27]; [@B64]). Furthermore, they demonstrated that glands from an inbred congenic *Cftr^-/-^* mouse strain responded to CCh but not to VIP or FSK similar to human CF glands ([@B64]). This study also documented that glands from CF mice did not secrete when they were exposed to chili oil, a treatment that produces secretion through stimulation of sensory nerves and the release of tachykinins, such as substance P. Additionally, it was demonstrated for the first time, that on tracheal SMGs of *Cftr^-/-^* mice, the substance P-stimulated fluid secretion requires CFTR ([@B64]).

The neuropeptide VIP is abundantly secreted around all exocrine glands including SMGs and sweat glands. It is well known to work in synergy with ACh to regulate secretions ([@B75]; [@B59], [@B60]). Interestingly, VIP KO mice generated in the C57BL/6 background demonstrated, *in vivo*, the central role of VIP in CFTR regulation ([@B16]; [@B4]). Originally developed to study airway diseases, such as bronchial asthma ([@B53]; [@B119]; [@B103]), VIP-KO mice were used by [@B4] to demonstrate the molecular link between VIP and CFTR regulation in the airways and small intestines, and observed a CF-like phenotype. The absence of VIP resulted in CFTR intracellular retention. A subsequent loss of CFTR-dependent chloride current was measured in functional assays with an Ussing chamber analysis of the small intestine *ex vivo*. In the lung, lymphocyte aggregation, increased airway secretion, alveolar thickening, and edema were observed. Inflammation and tissue damage observed in VIP-KO mice were attributed, at least in part, to the lack of CFTR-dependent secretions that rely on VIP stimulation of CFTR function. These observations support early findings of a lack of VIPergic innervation of human CF glands.

Nasal and Tracheal Epithelium
-----------------------------

Murine CF nasal epithelium exhibits two important characteristics of human CF airways: Na^+^ hyper-absorption and a defect in cAMP-mediated Cl^-^ secretion ([@B45]; [@B120]). Hyper-absorption of Na^+^ was demonstrated *in vivo* with an increased baseline PD across the epithelium that was largely decreased in the presence of the ENaC blocker, amiloride ([@B49]; [@B45]). In addition, the decreased level or absence of cAMP-stimulated Cl^-^ conductance was noticed in all murine models except for F508del *Cftr*^tm1Eur^. As mentioned above, the ∼10% residual normal CFTR expression in this model, may allow for a residual Cl^-^ permeability. In addition, nasal epithelium from *Cftr*^tm1Unc^ and *Cftr*^tm1Hsc^ demonstrates a Cl^-^ secretory response, which may be due to calcium dependent chloride channel (CACC) ([@B45]). The CACC is the prevalent Cl^-^ channel in murine tracheal epithelium ([@B97]). The gene that encodes this "pseudo" Cl^-^ channel is *TMEM16A*, and it was shown to be necessary for maintaining regular ASL levels. Studies on tracheas from *Tmem16a^-/-^* mice demonstrated more than 60% lower CACC activity and reduced MCC with mucus accumulation ([@B91]; [@B97]).

Despite bioelectric similarities, the murine nasal mucosa is composed of ∼40% olfactory epithelia and 60% RE, while the human nasal cavity is lined by more than 95% RE. However, the dominant cell type is the cilia cell, as in humans ([@B54]; [@B120]). In the *in vivo* analysis of *Cftr*^tm1Unc^, the nasal septal mucosa demonstrated goblet cell hyperplasia and enlargement correlated with reduced ASL height rather than changes in salt composition ([@B120]). A study using *Cftr*^Hm1G551D^ and *Cftr^tm1Unc^--TgN^(FABRCFTR)^* mouse models was conducted to examine whether the structural changes in nasal mucosa were related to infection and inflammation. Interestingly, they detected features that are comparable with human CF tissues, such as thickening of the RE with an increased number of mucus cells. The conclusion of the study suggested that the changes observed were not a consequence of initial inflammation ([@B61]). Another study from [@B48] using *Cftr*^tm1Unc^ mice reported that an ion transport defect in CF results in progressive morphological and structural changes in the olfactory epithelium of the nasal cavity ([@B48]).

The nasal cavity has been used extensively to investigate Cl^-^ permeability in response to corrector drug treatment by measuring the PD across the nasal epithelium. The murine nasal mucosa appears to offer an excellent model for investigating the abnormal electrophysiological profile of CF epithelial cells and testing potential corrector drugs. The murine trachea has also been used for studying cartilaginous rings alterations in *Cftr^-/-^* and F508del-CFTR mice. Structural modifications were observed in both newborn and adult CF mice independently of the CFTR absence or protein dysfunction and those changes could be indigenous ([@B9]).

Although the murine nasal cavity closely resembles that of humans and is easily accessible, most studies have rather used murine tracheal SMGs to examine MCC abnormalities and airway submucosal inflammation ([@B136]; [@B47]; [@B64]). Additionally, data from other animal models reported significant differences in size, density, secretory capacity and fluid secretion defects between nasal and tracheal glands. [@B64] suggested that the murine trachea is an appropriate tissue for studying airway glands abnormalities in CF ([@B64]). Airway SMGs are found in the proximal trachea of mice. In the cartilaginous rings, CFTR expression is found at the highest levels in SMG serous tubules as reported by [@B35]. Furthermore, it is well known that serous cells secrete antimicrobial proteins, such as lysozyme and lactoferrin, indicating the importance of tracheal glands in CF disease ([@B35]). Nevertheless, in murine trachea, the CACC exhibits "CFTR-like" activity and protects CF mice from having the severe lung phenotype that is observed in humans. Consequently, one must ask whether murine tracheal glands are appropriate for studying secretion abnormalities in CF. Until now, there has been no consensus about it.

Cystic Fibrosis Mice Develop Severe Postnatal Intestinal Disease
----------------------------------------------------------------

One of the earliest disease manifestations in CF is the MI in 15--20% of CF newborns and distal intestinal obstruction syndrome in 25% of adults ([@B140]). Moreover, CF mice are characterized by severe intestinal obstructions, including mucus accumulation, goblet cell hyperplasia, and crypt dilatation and elongation, symptoms similar to the human disease manifestations ([@B45]; [@B84]), which develop postnatally and appear to be the hallmark for all the CF mouse models ([@B46]; [@B67]) with the exception of only two mouse models (*Cftr*^tm1HGU^ and *Cftr*^tm1Eur^). The severity of the disease and the survival rate differ among genotypes ([@B46]; [@B33]; [@B15]; [@B28]). The neonatal death rate is ∼60% for CF null mice and only 35% for F508del-CFTR. However, this percentage of MI is still high compare to only 10% in the human disease. The *Cftr*^tm1Eur^ and *Cftr*^tm2Hgu^ models, carrying the F508del and G480C mutations, respectively, exhibit intestinal alterations that are not as severe as those in the *CFTR*-KO mice ([@B28]). The *Cftr*^tm1G551D^ has an approximate 70% survival rate with less severe pathology than the null models ([@B107]). A murine F508del model was generated with a replacement-gene targeting method by [@B22] and was suggested to be an accurate model for testing therapeutic drugs. It demonstrated severe meconium obstruction, reduced cAMP-stimulated Cl^-^ secretion, and the temperature-dependent trafficking defect that is described associated with this mutation in the human disease ([@B22]). Tissue sections of the colon and duodenum revealed huge crypt dilation with increased mucus accumulation. As previously mentioned, the genetic background variation and low residual level of expression of normal CFTR proteins have been proposed to explain dissimilarities between models.

Studies have shown that the expression of modifier genes may also be responsible for this intestinal variability. A genetic modifier of MI was detected in chromosome 19 in humans and on mouse chromosome 7 and was shown to be involved in the disease progression in KO mice ([@B102]; [@B140]; [@B52]). [@B84], using a DNA microarray, observed the presence of some gene expression associated with inflammation and presence of innate immune cells, such as mast cells and neutrophils, similar to those observed in the intestine of patients with CF ([@B84]). Amelioration of the intestinal obstruction and an increase in the survival rate was achieved by the expression of human CFTR cDNA in the intestinal track of *Cftr*^tm1Unc^ mice, under the control of the rat intestinal fatty-acid-binding protein (iFABP) gene promoter. This *Cftr^tm1Unc^--TgN*^(FABPCFTR)^ model enabled long-term studies in the intestine ([@B28]).

In a recent study, [@B78] investigated the efficacy of linaclotide in treating intestinal pathophysiology in CF mice carrying the F508del mutation or *Cftr-*KO mice. Linaclotide is a drug that has been approved by FDA to treat chronic idiopathic constipation. This study demonstrated that this drug elevates the amount of fluid in the intestinal lumen and improves intestinal transit, thus prompting the authors to recommend linaclotide as a therapeutic option to treat CF intestinal manifestations ([@B122]; [@B77]).

Electrophysiological studies have confirmed the ion transport abnormalities in CF mice with a similar phenotype to that of the human CF intestine: low or absence of cAMP-mediated Cl^-^ transport ([@B46]). Moreover, they display a significant reduction in the basal PD and short-circuit current (I~sc~) ([@B44]).

In summary, the CF murine intestine exhibits many pathophysiological similarities with that in humans with CF. However, it is important to categorize the different mouse models and background strains, the various techniques by which they were generated, the pathogen exposure, and the husbandry conditions during the research before evaluating the intestinal phenotype.

Cystic Fibrosis Mice Develop Mild Pancreatic Disease
----------------------------------------------------

In contrast to patients with CF in whom exocrine PI is a major condition, CF mice exhibit only moderate pancreatic changes ([@B109]). [@B33] demonstrated that a long-living CF-KO mouse bred into a congenic C57BL/6 background develops pancreatic pathology similar to humans with presence of inflammatory cells and macrophages and increased acinar volume at an older age ([@B33]). Surprisingly, mice with the F508del or G551D mutation, do not show any apparent pancreatic disease ([@B31]; [@B22]; [@B127]; [@B29]). The milder pancreatic disease in mice is attributed first to the lower level of normal CFTR protein expression in the murine pancreas, while high CFTR expression level has been shown in humans ([@B43]), and second to differences in the CACC channel expression. The CACC is detected in both WT and CF mice alleviating the pancreatic disease progression and perhaps explaining the mild murine pancreatic pathology ([@B76]; [@B21]; [@B43]; [@B67]).

Mice Sweat Glands -- An Underestimated Tissue in Cystic Fibrosis Research
-------------------------------------------------------------------------

Increased NaCl reabsorption abnormalities from sweat have been broadly studied with the sweat concentration being the most reliable pathophysiological marker. In mice, sweat glands are present in the palmoplantar skin (paw) ([@B73]). This tissue has largely been underutilized in CF research. In humans, sweat glands are controlled by adrenergic, cholinergic, and peptidergic innervation ([@B59]). [@B59] demonstrated a reduction of VIP, in the sweat glands of patients with CF ([@B59]). They proposed that, since VIP activates the opening of the CFTR channel, enabling the movement of water and Cl^-^ across epithelium, the lack of VIP innervation could cause low levels of water, Cl^-^ impermeability, and abnormalities involving other ions that manifest in CF disease. [@B105] investigated changes in cholinergic and β-adrenergic responsiveness during the postnatal life and reported that the mouse sweat glands are mainly under cholinergic control and express CFTR. Sweat secretion can be monitored in response to cAMP elevating agonists with activation of either K^+^ channels, Cl^-^ channels, or both. The secretion rates are higher in older animals (over 6-weeks old) but are independent from glandular enlargement. Additionally, Chappe et al. (personal communication) examined VIP expression in sweat glands of F508del mice and found support for the murine sweat glands as a valuable tissue for studying CF disease progression. Sweat glands remain free of infection, do not exhibit morphological alterations and are easy to collect. Accordingly, their use should be further evaluated for studying CF disease development and progression.

Porcine Models in Cystic Fibrosis Research
==========================================

Cystic Fibrosis Pigs Develop Lung Pathology Gradually
-----------------------------------------------------

The expression of the CACC channel in parallel with the CFTR channel in some mouse organs and the inability of mice to develop "spontaneous" lung disease led investigators to examine the pathology of the CF lung using other animal models. [@B99] recommended porcine airways as a possible model for CF because of their similar lung anatomy and morphological similarities with humans and identical bioelectric ion properties. [@B129], [@B130]) ([@B99]; [@B39]) developed the first CF pigs with homologous recombination, utilizing adeno-associated virus (rAAV) vectors to target the *CFTR* gene in fibroblasts from fetal pigs. A somatic cell nuclear transfer of these cells into oocytes was made to generate a heterozygous male pig and through heterozygous × heterozygous breeding, *Cftr^-/-^* piglets were born ([@B99]).

At birth, the lungs of the *Cftr^-/-^* piglets, like those of human CF infants, are normal with no signs of pathology ([@B100]). However, in contrast to control animals, BAL fluid from neonatal CF piglets revealed a large number of different bacterial species ([@B100]; [@B130]; [@B112]) and a rapid lung infection, which shows a more severe lung pathology than in patients with CF ([@B112]; [@B134]). When lungs from newborn WT and CF piglets were specifically challenged with *S. aureus*, the most common lung pathogen in infants and children with CF, only the CF piglets had more *S. aureus* than normal ([@B112]). That could be due to abnormalities in the pH of the ASL caused by reduced CFTR-dependent bicarbonate transport as reported by [@B93]. Newborn *Cftr^-/-^* pigs were also used to examine macrophage dysfunction and to determine if their defective polarization and function are due to the absence of CFTR, or a consequence of the chronic inflammation and infection. Data from this study suggested that defective macrophages function is present at the onset of the disease and is the cause of inflammation ([@B92]). Since the newborn CF pigs do not present signs of lung inflammation at birth, they are considered a good model for studying macrophages dysfunction prior to the beginning of the chronic inflammation.

Importantly, neonatal CF piglets have not been examined after a challenge with *P. aeruginosa*, and hence we do not know if CF pig airways are able to eradicate these bacteria. These data suggest that lungs from newborn CF pigs lack inflammation at birth but are unable to sterilize their lungs, suggesting that infection initiates inflammation ([@B134]).

The CF piglets revealed tracheal abnormalities, including narrowed proximal airways with thicker and more discontinuous cartilage, enlarged SMGs, and hyperplasia. Alterations in tracheal smooth muscle of F508del homozygote piglets were milder because of the residual CFTR function ([@B88]). These congenital tracheal alterations are similar to airway structural changes that occur in CF infants ([@B81]; [@B113]). It is suggested that the loss of CFTR produces tracheal abnormalities that may contribute to CF disease development during postnatal life ([@B100]; [@B130]). However, the specific mechanisms for these abnormalities and how the absence of CFTR during development induces these defects are still unknown ([@B81]).

While mucociliary transport plays a significant role in maintaining the airways sterile, it is still unknown if in CF it is defective from birth and contributes to the beginning of the disease or if it becomes defective later, contributing to disease progression. A study from [@B62], established a new *in vivo* mucociliary transport assay (X-ray-computed tomographic-based method) with newborn pigs, which provides important insight into the pathophysiology of CF, as well as other respiratory diseases, at their early stages. The authors analyzed the movement of particles in bulk, and individually, in the large airways. They found that cilia orientation directs particles to the ventral area of the trachea and to the larynx, while the rate of individual particle's movement was largely heterogynous. They speculate that different mucus properties may account for this heterogeneity ([@B62]). Moreover, using 350 μm diameter tantalum microdisks, they found that CF SMGs secrete dense mucus strands that remained tethered and prevent the movement of those dense disks. The authors conclude that impaired mucus detachment from SMGs could be an early defect in CF ([@B63]).

The development of lung disease in CF pigs is not easy to investigate because most of them die from MI that occurs in 100% of the piglets ([@B100]; [@B130]; [@B82]; [@B112], [@B114]; [@B85]). A study from [@B112], performing an ileostomy on CF pigs that survived approximately 2 months or more, demonstrated the presence of structural, bacteriological and inflammatory markers of CF. Part of the airways were characterized by the presence of macrophages, neutrophils and bacteria, similar to those in human airways. [@B88] demonstrated that, despite residual CFTR expression, older *Cftr*^F508del/F508del^ pigs exhibited lung disease similar to humans, rendering the minimal CFTR activity observed (∼6% to WT function) insignificant for lung pathogenesis. A study from [@B108] demonstrated that CF pigs, like humans, have ASL acidification in contrast to mice. This is thought to be due to ATP12A in absence of CFTR chloride channels. Acidification of the ASL impairs airway defense while ATP12A inhibition, which increases the pH, improves host defense properties of the ASL in CF pigs ([@B108]).

Although CF pigs recapitulate most of the human manifestations of CF, only a small number have been used for studying CF pathology, mostly due to the difficulty of keeping them alive long enough. Even after an ileostomy or cecostomy to cure MI, 60% of the piglets still had to be euthanized for gastric ulcers ([@B112]; [@B134]; [@B85]). Long-term research still needs to be conducted to validate the data.

Porcine Submucosal Glands -- Excellent for Studying Secretion
-------------------------------------------------------------

Porcine lungs highly express CFTR proteins in the serous cells of SMGs of the cartilaginous airways, and, as in humans, exhibit the same secretion abnormalities in CF animals, with no detected morphological changes ([@B100]; [@B130]). [@B17] demonstrated a lack of cAMP-mediated Cl^-^ transport and subsequently impaired bicarbonate (HNO~3~^-^) transport with an absence of sodium hyper-absorption or reduction in ASL depth ([@B17]). This finding in CF pigs, with no signs of inflammation at birth, contradicts the hypothesis that Na^+^ hyper-absorption might trigger lung disease. The authors suggested that defects in Cl^-^ and HNO~3~^-^ initiate lung pathology and not deviations in sodium transport ([@B17]; [@B113]).

Ion transport abnormalities were detected in nasal airway epithelia from CF piglets with a hyperpolarized baseline transepithelial voltage (Vt), while the addition of amiloride (ENaC inhibitor) decreased the Vt in all CF piglets ([@B98],[@B100]; [@B130]). Perfusion of the apical membrane with a solution containing low Cl^-^ concentration and isoproterenol (to elevate cAMP) hyperpolarized nasal Vt in WT and heterozygous but not in *Cftr^-/-^* pigs ([@B98],[@B100]; [@B65]). Lastly, perfusion with ATP to stimulate P2Y2 receptors and CACC channels produced further hyper-polarization while the CFTR inhibitor glybenclamide depolarized Vt in *Cftr*^+/+^ and *Cftr*^+/-^ but not in *Cftr^-/-^* piglets, demonstrating that a lack of CFTR channel function causes electrolyte transport abnormalities in airway epithelia ([@B100]; [@B130]). The CFTR selective inhibitor CFTRinh-172 was found to be less effective with the porcine protein compared to the human CFTR ([@B98]). [@B71] have reported species-specific differences in airway epithelial electrolyte transport and CFTR function ([@B71]).

Nasal vs. Tracheal Submucosal Glands
------------------------------------

Human CF SMGs only secrete minimally in response to agonists that increase intracellular cAMP alone (VIP and FSK) or slightly to agonists that elevate \[Ca^2+^\]~i~ (substance P and CCh) ([@B20]). The combination of these two types of agents produce a synergetic response that is lost in CF. Accordingly, [@B65] showed that tracheal SMGs from CF piglets did not respond to FSK but did respond to CCh, while substance P proved to be more efficacious in CF pigs than in humans. In contrast to human SMGs, *Cftr^-/-^* pigs exhibited synergistic secretion which was attributed to CFTR-independent pathways ([@B65]). Future studies on the specific mechanisms are necessary and would clarify whether this tissue is appropriate for studying fluid secretion defects in CF disease.

Interestingly, a study from [@B89] demonstrated that tracheal SMGs from CF pigs produce mucin 5B (MUC5B) while goblet cells produce mainly mucin 5A (MUC5AC) and moderate MUC5B. The same study suggested that these two types of mucins have different morphologic structures that account for a more effective MCC transport ([@B89]).

[@B18] described morphological and fluid secretion differences between nasal and tracheal glands in CF piglets. In contrast to tracheal glands, nasal glands were found to be smaller and more numerous than in humans ([@B18]) with no response to FSK and a moderate response to CCh, while the synergy was almost lost ([@B65]). These findings are of high interest because, as [@B100] showed, CF piglets have abnormal ion transport in nasal epithelium ([@B100]) which could contribute to lung pathology in CF when combined with defective fluid secretion from nasal glands.

Intestinal Obstruction Is Fatal in Cystic Fibrosis Piglets
----------------------------------------------------------

Meconium ileus is 100% fatal for CF pigs and a surgical ileostomy must be performed right after birth so as they can survive longer ([@B130]; [@B82]; [@B114]). Accordingly, to suppress intestinal obstruction, [@B114] used the rat intestinal fatty-acid-binding protein promoter (iFABP) to express WT porcine CFTR proteins (pCFTR) in *Cftr^-/-^* "gut-corrected" pigs ([@B114]). Their data supported the hypothesis that approximately 20% of CFTR expression was adequate to partially restore CFTR-mediated Cl^-^ transport. Similar to *Cftr^-/-^* and *Cftr*^F508*del*/F508*del*^ pigs, these transgenic animals developed pancreatic, liver, and lung disease and therefore failure to thrive ([@B114]). The expression of CFTR proteins in parts of the intestine, other than in ileum, might be important for improving the MI defect. Gut correction was tested only in neonatal CF pigs and hence it is not known yet if the required amount of CFTR function during adult life would be the same. Nonetheless, while surgical gut correction is not always successful, this transgenic model would be another method for making these animals live long enough (up to 12 months) to study disease progression.

Interestingly, while one would expect less disease severity in *Cftr*^F508del/F508del^ pigs compared to null animals, due to residual function of CFTR (∼6% of WT), they still show 100% penetrance of MI, as was reported by [@B88]. In general, MI in CF pigs closely resembles the disease in humans, while distinct anatomy or physiology in combination with the differences in genetic background between pigs and humans may account for the dissimilarity of penetrance rate.

Porcine Pancreatic Pathogenesis Is Closely Similar to Humans
------------------------------------------------------------

Cystic fibrosis pigs closely recapitulate pancreatic pathogenesis of humans CF with varying levels of disease severity among genotypes ([@B100]; [@B82]). After surgical correction of MI, PI develops spontaneously in these animals ([@B67]). The exocrine pancreas in newborn *Cftr^-/-^* pigs, as in human CF neonates, is smaller than normal, with degenerative lobules containing loose adipose tissue, mild, scattered inflammation, and dilated ducts with eosinophils, neutrophils, and macrophages. The endocrine tissue is intact, spared from the surrounding exocrine destruction with fewer acinar cells and zymogen granules ([@B100]; [@B130]; [@B82]). Insulin-immunoreactive islets are mostly localized on the intact lobular tissue without alterations in the amount of insulin produced or glucagon cells. The volume and pH of pancreatic fluid are reduced in CF neonatal pigs, as in humans, with increased protein concentration ([@B41]).

Interesting data from [@B3] in fetal and newborn *Cftr^-/-^* and *Cftr*^F508del/F508del^ pigs demonstrated that tissue damage starts *in utero* and pro-inflammatory, complement cascade, pro-apoptotic, and pro-fibrotic pathways are involved ([@B3]). They noticed elevated activation of the apoptotic caspase-3 pathway in the CF pig pancreas whereas the α-smooth muscle actin, a myofibroblast marker and activator of early fibrosis pathways, was observed in both fetal and newborn pigs. Tissue remodeling with mucus accumulation and duct cell proliferation was observed in the neonatal and not in fetal CF pigs, indicating that these changes do not initiate disease pathogenesis but follow pancreatic damage over time. Compared to *Cftr^-/-^*, *Cftr*^F508del/F508del^ pigs exhibit slightly less severe exocrine pancreatic pathogenesis that may be attributed to the residual CFTR function ([@B88]). Future studies that investigate how much CFTR chloride channel function is necessary for the correction of pancreatic disease would be a fundamental knowledge for the progression of CF pathogenesis. Studies in adult CF pigs would be useful and would enhance our understanding of pancreatic damage in humans.

Ferret Models in Cystic Fibrosis Research
=========================================

Comparable Lung Pathogenesis With Cystic Fibrosis Patients
----------------------------------------------------------

The lungs of ferrets share many similarities with human lungs in terms of function and architecture, and like CF pigs, CF ferrets develop spontaneous lung infections soon after birth ([@B117], [@B115]; [@B66]). Similar to pigs, CF ferrets were produced using homologous recombination. The first genetically designed CF ferret was described by [@B118], utilizing rAAV-mediated targeting of the *CFTR* gene in fetal fibroblasts followed by nuclear transfer cloning ([@B118]). The *Cftr^-/-^* ferrets develop severe lung pathology within the first weeks of life, and like piglets, they are unable to eliminate bacteria. Data from the BAL fluid of newborn CF ferrets revealed various bacterial species including *Streptococcus*, *Staphylococcus* and *Enterococcus* genera while three species of *Pseudomonas* (*P. fluorescents, P. putida* and *P. fulva*) were found in low amounts ([@B117], [@B115]). In addition, macrophages from CF ferrets produce high levels of cytokines after being challenged with pathogens such as *P. aeruginosa*, *Bcc* or challenged with LPS ([@B11]). Interestingly, a study from [@B66] demonstrated differences in BAL fluid composition from CF and WT animals ([@B66]). Levels of lactoferrin and lysozyme were especially increased in the naturally born CF ferrets in contrast to those delivered by C-section, while α~1~-antitrypsin and apolipoprotein A1 were reduced following natural birth but remained unaltered in animals delivered by C-section ([@B66]). Moreover, proteins related to neutrophil activity were raised in naturally born CF ferrets but absent in those delivered by C-section. The authors measured levels of inflammatory cytokines (IL-1β, IL-8, and TNF-a). They did not find any alteration between C-sectioned CF and non-CF ferrets while the newborn CF animals exhibited lower levels of IL-1β, but IL-8 and TNF-α were higher, similar to infants with CF.

Thus, they concluded that inflammatory dissimilarities in CF ferrets may start *in utero* and result in excessive inflammation during birth, following bacterial exposure ([@B66]). These data suggest that innate immunity and inflammatory pathways change under sterile and non-sterile conditions, making these animals a valuable model for studying the early onset and progression of CF disease.

Adult CF ferrets do not show abnormal inflammatory response. However, they have other similarities in lung pathology with humans, such as airway obstruction, thick mucus accumulation, and inflammation ([@B115]).

Postnatal Development of Submucosal Glands
------------------------------------------

In ferrets, as in humans, the CFTR protein is highly expressed in serous cells of SMGs lining their cartilaginous rings. Newborn ferrets do not have ciliated cells or SMGs, but they develop them abundantly a few months after birth ([@B115]; [@B66]). A study from [@B66] on newborn *Cftr^-/-^* ferrets reported that tracheal MCC was similar to non-CF ferrets, while ASL height was decreased. Only 1--3 weeks after birth, when MCC rate slightly increases, CF related MCC abnormalities would have an impact on the lung pathology ([@B66]). Additionally, [@B115] demonstrated a seven-fold decrease in MCC in adult compared to juvenile *Cftr^-/-^* ferrets that was attributed to an age-dependent ENaC hyperactivity ([@B115]). The unique characteristic of ferret lungs to develop SMGs postnatally suggests the presence of CFTR-independent mechanisms that cause the early lung inflammatory profile and future investigations will be valuable.

Ferret Trachea Is Appropriate for Studying Gland Secretion
----------------------------------------------------------

Adult ferrets have an abundance of tracheal glands, and like humans, they depend on Cl^-^ and HCO~3~^-^ for secretion (CFTR-dependent). In adult WT ferret tracheas, [@B19] revealed a reduced secretion rate by blocking Cl^-^ or HCO~3~^-^ in response to VIP or FSK. Additionally, CCh-induced MCC was highly decreased when blocking the Na^+^-K^+^-2Cl^-^ (NKCC) co-transporter with bumetanide. The authors showed synergistic secretion when low concentrations of agonists that elevate \[cAMP\]~i~ were combined with low concentrations of agonists that elevate \[Ca^2+^\]~i.~ Neonatal ferret tracheas contain few cells that express high levels of CFTR since SMGs are not yet developed. Studies on newborn *Cftr^-/-^* ferrets have shown abnormal fluid secretion from their tracheas in response to FSK and CCh, with higher reduction to FSK stimulation, similar to data from human proximal CF airways ([@B117]).

As CF ferrets have a similar airway morphology to humans, they are a good model for studying CF pathogenesis. They develop human-like lung disease and CFTR-dependent secretion in trachea, albeit the amiloride-sensitive transepithelial PD was unaltered between CF and non-CF ferret tracheas. However, research in CF ferret fluid secretion is spare, and while it seems a promising animal model, our knowledge has been limited until now.

Intestinal Disease Is More Severe in Ferrets Compared to Humans
---------------------------------------------------------------

Newborn CF ferrets, like CF piglets, present a higher incidence of MI than seen in human infants with CF. Between 50% and 100% of CF ferrets develop MI and die within 36 h due to intestinal obstruction and sepsis ([@B39]). Most of CF ferrets that survive MI still fail to thrive soon after birth because of malabsorption. Compared to other animals, they do not have caecum and therefore have less time to digest ([@B117]). A study from [@B116] in CF ferrets over a month old reported that the small intestine was characterized by a reduction in the height of the villi and mucus accumulation in the crypt with signs of inflammation within the lamina propria and into the epithelium ([@B116]). A metagenomic deep sequencing analysis revealed the exacerbation of *Streptococcus*, *Enterococcus*, and *Escherichia* in CF ferret feces, similar to what occurs in CF infants ([@B116]). A gut-corrected transgenic model that expresses the *CFTR* gene under the control of the rat fatty acid-binding protein promoter (iFABP), is shown to correct MI in newborn *Cftr^-/-^* ferrets ([@B117]). The generation of a F508del-CFTR ferret would be useful to increase our knowledge of CF with the most common mutation.

Pancreatic Insufficiency Occurs the First Months of Life
--------------------------------------------------------

Newborn *Cftr^-/-^* ferrets exhibit mild pancreatic pathology, similar to CF human infants, and are characterized by swollen acini and ducts with eosinophilic zymogen material, moderate alterations and pancreatic lesions observed in approximately 75% of *Cftr^-/-^* ferrets ([@B67]; [@B116]). [@B86] demonstrated that neonatal CF ferrets exhibited elevated apoptosis in exocrine ducts and acini suggesting that pancreatic inflammation starts very early in life. Within the first month of life and before adulthood, the pancreas undergoes rapid tissue deterioration with destruction of acini, duct dilatation and evidence of inflammatory cells (neutrophils, macrophages and lymphocytes) ([@B86]). Similar to patients with CF, 85% of adult CF ferrets present a loss of exocrine pancreas with fibrosis and islet remodeling. Interestingly, a small percentage of CF ferrets, like patients with CF, are born PS with light pancreatic pathology while they have normal growth and fecal elastase-1 (EL1) levels ([@B116]). This finding demonstrates that, as in patients with CF, modifier genes could be responsible for this small percentage of PS. Additionally, adult CF ferrets exhibit disorganized islets, characterized by large clusters that contain an abundance of β and α cells as occurs in the pancreas of humans with CF ([@B86]). In general, CF ferrets share many features of human pancreatic disease, and their ability to exhibit variability of disease severity at birth and in adulthood makes them an excellent model for testing potential therapies and examining the specific mechanisms for PI in CF.

Lung and Intestine Observations in a Recent Cystic Fibrosis Rat Model
=====================================================================

The first CF rat model was generated by [@B125] with the use of the zinc-finger endonuclease technique. Rats are an appealing model for studying airway defects in CF because they share many characteristics consistent with humans. In contrast to mice, where SMGs are only located at the proximal trachea, rats SMGs extend to bronchi as in humans. The *Cftr^-/-^* rats, shortly after birth, exhibit congenital tracheal defects with a reduction in the cartilage and tracheal gland area ([@B125]). Nasal PD measurements demonstrated loss of Cl^-^ permeability in response to FSK, suggesting that the absence of CFTR chloride channels changes electrophysiological features in the rat ([@B125]). Additionally, young CF rats revealed reduced amounts of ASL in distal airways, similar to humans, while BAL fluid was free of inflammatory markers. The decreased ASL levels were not accompanied with Na^+^ hyper-absorption suggesting that ASL regulation was CFTR and not ENaC dependent ([@B125]). Young CF rats did not show rapid pulmonary pathology progression, while the sterile environmental conditions under which they were kept may have had an effect ([@B125]). Future studies that will examine disease progression in adult CF rats housed in a natural environment will clarify the role of ASL depletion in airway obstruction. The presence of an increased number of dilated mucus cells was noticed in the proximal nasal epithelium, adding another similarity with the human pathology.

A study from [@B123] investigated nasal septal epithelial cultures from *Cftr^-/-^* rats and demonstrated that they would be a useful model for *in vitro* sinosal ion transport studies. The authors demonstrated that those cell cultures have comparable *Cftr* gene expression and nasal electrophysiological properties to nasal septal epithelial cultures from human and mice, while being more responsive to ion transport modulators ([@B123]). Moreover, a recent study from [@B8] demonstrated that the development of the SMGs is delayed in the *Cftr^-/-^* rats but only when the SMGs are fully developed, elevated mucus viscosity and impaired mucociliary transport were observed. Hyperacidic pH and changes in the periciliary layer, however, happen before SMGs develop. Importantly, blocking bicarbonate transport increased mucus viscosity. Additional studies on secretion abnormalities in tracheal glands using CF rats will add important information.

In addition, 70% of *Cftr^-/-^* rats mortality is due to intestinal obstruction between weaning and 42 days after birth in contrast to piglets and ferrets that suffered from severe intestinal obstruction at birth. Their small intestine was characterized by crypt dilation and mucus accumulation ([@B125]).

While CF rats do not spontaneously develop lung or pancreatic disease during their first 6-weeks of life, they are a good model for investigating bone growth and its direct link to CFTR, without the presence of other disease manifestations such as airway disease. Accordingly, [@B111] examined the role of CFTR loss on bone growth using young *Cftr^-/-^* rats by measuring their femur length, bone histomorphometry and cartilaginous growth plates as well as the concentration of serum IGF-I. Deficiency in IGF-I can cause changes in cartilage growth. They found that in absence of the *CFTR* gene, rats show reduced growth and bone content. Also, IGF-I concentration in the serum of *Cftr^-/-^* rats (a marker also used in non-CF children with bone disease) is decreased, which may explain changes in the growth plate ([@B111]).

In general, the *Cftr^-/-^* rat is a promising model for long-term studies of CF disease manifestations. Although it is in the early stages, this model could be the base for generating CF rats with disease-causing mutations that would allow investigations of CFTR protein trafficking or gating defects and CFTR correctors and potentiators.

Cystic Fibrosis Zebrafish -- a Unique Model of Pancreatic Disease Progression in All Developmental Stages
=========================================================================================================

Zebrafish have been valued as an outstanding tiny research model for studying human diseases. They are inexpensive, and can be generated in large numbers, while requiring minimal housing and handling conditions ([@B94]). Moreover, zebrafish CFTR chloride channels responds similarly to most agonists and antagonists of the human CFTR due to its high homology. Data have demonstrated that the absence of CFTR in zebrafish hinders the development of Kupffer's vesicle (KV), a basic ciliated organ, which determines lateralization in an early developmental zebrafish stage, emphasizing the importance of CFTR function in fluid secretion ([@B83]).

The first zebrafish CF model was produced by [@B83] using transgenic zebrafish mutant lines. They reported that CFTR was localized on the apical membrane of pancreatic ducts and investigated the absence of CFTR in zebrafish pancreas during various developmental stages suggesting comparable disease pathology as in humans. They reported that most of CF larval zebrafish started to die approximately 10 days post fertilization (dpf), suggesting that pancreatic dysfunction starts early in life. By 16 dpf, pancreatic tissue was partially damaged and neutrophil presence was slightly evident while by 20 dpf, the pancreas was remarkably disrupted. Pancreatic ducts contained mucus, and they were encircled by fibrotic tissue instead of acinar and were highly infiltrated with neutrophils. Additionally, the islets appeared widespread, abundant and diminished in size. The CF zebrafish model closely resembles pancreatic pathogenesis in human adults with CF suggesting that a mild PI may start early in life. Additional studies examining the specific mechanisms that cause pancreatic disease early in life, the role of the inflammatory factors in disease progression, and the ion transport abnormalities using the zebrafish model would be very valuable tools for pancreatic pathogenesis in CF.

Sheep CF Model -- a Brief Description of an Attractive Undervalued Model
========================================================================

The sheep model is not a commonly used model for studying CF disease compared to mice, pigs and ferrets, respectively. However, at the molecular level, the sheep *CFTR* gene is 91% homologous with the human *CFTR* while at protein level, they have 95% resemblance ([@B55]). Many researchers have used an ovine model for studying respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) since anatomically, functionally and electrophysiologically sheep airways parallels those of humans ([@B2]; [@B5]). It has been utilized for examining secretion abnormalities, testing the effect of small molecules as a potential therapy for lung disease and for gene therapy ([@B14]). Apart from the lung pathology, CFTR protein expression in sheep pancreas mirrors human levels. As a large animal, in combination with its long lifespan, it could be appropriate for therapeutic trials. Generation of a CF ovine model utilizing somatic cell cloning was not successful in the past due to failure of homologous recombination in sheep fibroblasts. In 2018, Fan et al. generated the first *Cftr^-/-^* sheep model using the CRISPR/Cas9 genome editing and somatic cell nuclear transfer methods. The newborn *Cftr^-/-^* sheep demonstrated severe intestinal obstruction similar to the MI noticed in approximately 15% of human babies with CF. The pancreas was characterized by hypoplasia and fibrosis similar to humans with CF. This pancreatic hypoplasia was common in both KO and heterozygous sheep. Interestingly, lungs of newborn *Cftr^-/-^* sheep had minimal signs of disease which is an important feature that enables investigations of early disease progression ([@B36]). Production of a CF sheep model gave rise to a new chapter of large animals as useful models for novel therapeutic approaches.

Discussion
==========

Despite recent research progress, our understanding of CF pathogenesis is still incomplete. Many questions remain unanswered and CF continues to be a fatal disease. Cell-culture models have been shown to be useful for pre-clinical trials but they lack the structural complexity of intact organs ([@B106]; [@B100]; [@B24]). Much of the knowledge on CF pathophysiology that we have today derives from animal models and especially from the wide variability of gene-targeted mouse models. Most of the studies repeatedly note that mice models, in contrast to pigs and ferrets, do not spontaneously develop lung disease as do humans. However, depending on the strain, such as congenic models with the C57BL/6 background, they have the advantage of surviving longer from intestinal disease and are susceptible to lung infection with pathogens, mainly the most persistent *P. aeruginosa*. Pigs and ferrets exhibit similar lung function and architecture with humans and at birth they lack inflammation, and they are unable to eradicate bacteria ([@B100]; [@B112]; [@B117]; [@B134]; [@B88]). The disadvantage of these models is the difficulty of keeping them alive long enough since, approximately 48 h after birth they die from intestinal obstruction and a surgical ileostomy is mandatory but not always successful. Consequently, while most of the studies report a lung pathology similar to that in patients with CF, they are only based on experiments that have been conducted in very few animals, mostly newborn ([@B100]; [@B65]; [@B112]; [@B117], [@B115]; [@B134]; [@B88]; [@B66]).

Mice SMGs, contrary to those in rats that extend into the bronchi, are confined to the trachea, but they are abundant and identical in structure to those in humans. Despite the bioelectric similarities of murine nasal SMGs with those in humans, tracheal glands are widely utilized due to the highest expression levels of CFTR proteins, whereas studies on *Cftr^-/-^* mice have demonstrated secretion defects. Tracheal glands from CF pigs also exhibit secretion defects but they do not completely lose synergy as mice or newborn CF ferrets do ([@B65]). Secretion defects are restricted only in newborn CF ferrets and CF pigs, in contrast to mice, while studies in CF ferret nasal glands have not been done yet ([@B117], [@B115]; [@B66]). The dominance of the CACC channel in mice airways, intestine and pancreas, in parallel with CFTR proteins, alleviate the severity of the disease pathogenesis compared to other models. Intestinal pathology can be fatal for some CF mice, causing death a few days after birth or around the time of weaning ([@B25]). The disease severity varies among strains and although it is more severe than in humans, CF mice intestine still exhibit the same pathophysiological abnormalities, and they are considered a good model for studying human intestinal disease.

In addition, MI is fatal for both CF piglets and ferrets with a penetrance of 100% and 50--100%, respectively, while the occurrence in human infants with CF is only moderate at 15--20%. The generation of transgenic mice, pigs, and ferrets with tissue-corrected *CFTR* gene expression under the control of the iFABP gene promoter alleviates intestinal obstruction with no effects on the other organs. Interestingly, milder pancreatic disease is observed in CF mice, while CF pigs and ferrets that survived from MI demonstrated human-like disease. However, studies in adult pigs and ferrets are limited. The first CF zebrafish model enabled the examination of pancreatic pathogenesis in all developmental stages, demonstrating that a mild pancreatic disease starts early in life ([@B83]).

Although human CF is characterized by salty sweat, eccrine sweat glands are underestimated in the above CF animal models. Pigs use mud baths to cool their body ([@B98]) as they have very few sweat glands, which are in the nose, while ferrets do not sweat at all. Importantly, mice have sweat glands in their paws, this is a promising tissue for studying CF disease which should be further evaluated.

Conclusion
==========

In conclusion, while various animal models present different advantages for studying different aspects of the disease, there is no single animal model available yet that completely replicates the complexity of CF in humans. Each model presents pros and cons and combining findings from various organs studied in different models provides important clues for our understanding of the CF disease pathogenesis and progression.
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